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RExercise Restrictions After
Balloon Aortic Valvuloplasty
We read with interest the study of outcomes after balloon aortic
valvuloplasty recently published by Brown et al. (1), and the
accompanying editorial by Rome (2). The authors have valuably
demonstrated the outcome of patients who have had balloon aortic
valvuloplasty and shown that sudden death in this young patient
population is rare. Their paper and Dr. Rome’s editorial also
remind readers that any recommendations for exercise restrictions
in these patients are not evidence-based and that such restrictions
have risks as well as benefits.
Many of us rely upon the 36th Bethesda Conference guidelines
(3) when imposing restrictions on our young patients. These
guidelines, however, are intended for competitive athletes and not
for young children. They are stated to be “most easily applied to
high school, college, and professional sports” with deference to the
clinician’s individual judgment for youth sports activities, “partic-
ularly for those children less than age 12 years” (3).
The authors’ choice to extend the evaluation of exercise restric-
ion in aortic stenosis down to patients as young as 4 years of age
ncreases the number of patient-years in the assessment, but
erhaps not in a meaningful way. In the subgroup of 403 patients
n whom an exercise recommendation could be determined, many
atients were not old enough for such a recommendation to be
pplicable for much of the study period. In those patients with an
xercise restriction, follow-up began at a mean age of 4 years and
asted for an average of 14.4 years. Those in whom there was no
xercise restriction began follow-up at a mean age of 3 years for an
verage duration of 12.1 years. If one limits the data to those
atients old enough to participate in competitive sports, and
urther to those who chose to participate, the study sample size and
vailable years of follow-up would decrease significantly. To
ppropriately assess the population of young athletes at highest
heoretic risk for life-threatening events will likely require a larger,
ulticenter study.
Brown et al. (1) should be congratulated for lighting a candle in
he darkness of our understanding of sudden death in the context
f aortic stenosis, and they raise important questions about our
ecommendations for our patients’ activity. Unfortunately, it is still
retty dark out there.
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Reply
We thank Drs. Hokanson and Ralphe for their interest in our
paper and comments on our findings (1). Although the Bethesda
Conference guidelines were written to apply to patients 12 years of
age and older, this age was arbitrarily chosen by the consensus
committee as an age at which participation in organized sports
with systematic (usually intense) training and regular competition
becomes common. However, the consensus panel clearly recog-
nized the possibility of application to all ages, and noted that
clinicians “may want to use individual judgment in defining
competitive forms of physical activity . . . particularly those for
children less than age 12 years” (2). In our experience, organized
athletics with intense training and competition are quite common
in the United States in those younger than age 12 years, and many
clinicians do apply these restrictions to patients as young as 4 years;
hence, we chose to include those patient-years in our follow-up.
The assumption that any exercise-associated risk of sudden
death is highest in young athletes is based on theoretical consid-
erations and not on documented risk. We agree that it requires
extremely large studies to establish an absence of risk. Unfortu-
nately, case reports and case series that are void of any statistical
considerations are often accepted as evidence of risk and, in the
absence of better data, are used to develop consensus guidelines.
This situation is quite parallel to the recommendations for sub-
acute bacterial endocarditis prophylaxis in patients with congenital
heart disease, where case reports rather than population-based
studies of endocarditis were used to justify population-wide man-
agement, recommendations that have subsequently been rescinded.
This prejudice is prevalent throughout medicine and proceeds
from the justifiable desire to minimize risks. However, as is the
case with young patients with aortic stenosis, sometimes avoidance
of theoretical risk means exclusion of activities with clinically
proven benefit.
The issue the practicing clinician faces on a daily basis is
whether a theoretical, but unproven, risk should prompt an
exclusion from athletics participation with all of the extremely
well-documented benefits of vigorous exercise. The risk-benefit
considerations here are quite complex because regular exercise
participation has been clearly documented to reduce overall risk of
sudden death, even if there is a transient increase in risk during
exercise (3–7). It is therefore insufficient to proceed on data
collected only during exercise participation, which is the nature of
RR
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May 17, 2011:2034–6the case report data that have been used to argue in favor of
exercise restriction in patients with aortic stenosis. As we contem-
plate cost-effective means of compiling a much larger dataset that
will improve the confidence intervals we can apply to both the risks
and benefits of exercise participation in this population, practicing
clinicians will need to continue to make this judgment on a daily
basis. Our data undoubtedly do not absolutely exclude the possi-
bility of an increased risk of exercise-associated sudden death in
subjects with aortic stenosis, but they certainly provide no evidence
to support it. This, coupled with the clear evidence of benefit from
regular exercise participation, lead us to the opinion that current
evidence does not support continuation of these restrictions.
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Cilostazol: A Potential
Therapeutic Option to
Prevent In-Stent Restenosis
It was of great interest and utility to read the paper by Dangas
et al. (1) pertaining to in-stent restenosis (ISR) in drug-eluting
stents (DES). The authors reviewed systematically the pathophys-
iological, mechanical, and technical mechanisms and treatment
options of ISR in DES. The proposed treatment algorithm is an
important clinical tool for a challenging problem without a proven
treatment regimen. We would like to present another possible
treatment option available for ISR. We believe that the plateletphosphodiesterase III (PDE III) inhibitor cilostazol may poten-
tially have a beneficial role in the treatment of ISR in DES.
Cilostazol is approved and widely used for the treatment of
intermittent claudication. It has properties that inhibit several
biological mechanisms, such as smooth muscle proliferation, which
may lead to ISR (2). PDE III inhibitors reduce P-selectin
expression on platelets and Mac-1 on the surface of neutrophils.
Mac-1 has been shown to be a key protein involved in neointimal
hyperplasia and in the pathophysiology of ISR, and rises during
the 48 h after PCI (3).
In previous clinical trials, it has been shown that PDE III
inhibitors reduce the rate of ISR. In the CREST (Cilostazol for
REStenosis Trial), cilostazol was shown to significantly reduce
neointimal hyperplasia and the rate of restenosis in a population of
patients undergoing bare-metal stent implantation (4). Cilostazol
has also been shown to reduce the rate of ISR in patients treated
with DES. In a group of diabetic patients treated with DES,
cilostazol was shown to reduce the rate of angiographic restenosis
and target lesion revascularization without an increase in severe
adverse effects (5). In 1 trial, cilostazol therapy showed a 40.2%
relative risk reduction in ISR in patients with DES of 32 mm
(6). Patients in the trial were also noted to have significantly lower
rates of in-segment and in-stent late loss, as well as a reduced rate
of target vessel revascularization. A recent meta-analysis of the
effects of cilostazol in patients treated with both bare-metal stents
and DES found that in 2,809 patients pooled from 10 different
randomized trials, cilostazol reduced late loss by a mean difference
of 0.15 mm. Binary angiographic restenosis was also significantly
lower in patients treated with cilostazol, regardless of the type of
stent used (7).
The use of cilostazol to prevent ISR has shown promise in the
limited clinical trials available. These trials are not without
limitations. Adding cilostazol use would subject patients to an-
other antiplatelet agent that could potentially lead to an increased
bleeding risk. It should also be noted that the clinical trials
mentioned have a rather limited follow-up period, and the patient
population in those studies is not ethnically diverse. Cilostazol was
also used in the study population as an agent for primary
prophylaxis and not as a secondary therapy. Though little definitive
evidence is available, we believe that the data for the use of
cilostazol to prevent ISR are promising, warrant further investiga-
tion, and may provide clinicians with another therapeutic option.
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